MX2021009796A - Inhibidores selectivos de la proteina arginina metiltransferasa 5 (prmt5). - Google Patents

Inhibidores selectivos de la proteina arginina metiltransferasa 5 (prmt5).

Info

Publication number
MX2021009796A
MX2021009796A MX2021009796A MX2021009796A MX2021009796A MX 2021009796 A MX2021009796 A MX 2021009796A MX 2021009796 A MX2021009796 A MX 2021009796A MX 2021009796 A MX2021009796 A MX 2021009796A MX 2021009796 A MX2021009796 A MX 2021009796A
Authority
MX
Mexico
Prior art keywords
prmt5
selective inhibitor
protein arginine
arginine methyltransferase
crystalline forms
Prior art date
Application number
MX2021009796A
Other languages
English (en)
Inventor
Mark Andres
Hong Lin
Qun Li
Huaping Zhang
Original Assignee
Prelude Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prelude Therapeutics Inc filed Critical Prelude Therapeutics Inc
Publication of MX2021009796A publication Critical patent/MX2021009796A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

La descripción está dirigida a formas cristalinas del compuesto de la Fórmula I, sales farmacéuticamente aceptables del compuesto de la Fórmula I y formas cristalinas de los mismos. (ver Fórmula) También se describen composiciones farmacéuticas que comprenden dichas formas cristalinas y sales, así como también métodos para su uso y preparación.
MX2021009796A 2019-02-13 2020-02-13 Inhibidores selectivos de la proteina arginina metiltransferasa 5 (prmt5). MX2021009796A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962805175P 2019-02-13 2019-02-13
US201962805726P 2019-02-14 2019-02-14
PCT/US2020/018185 WO2020168125A1 (en) 2019-02-13 2020-02-13 Selective inhibitor of protein arginine methyltransferase 5 (prmt5)

Publications (1)

Publication Number Publication Date
MX2021009796A true MX2021009796A (es) 2021-09-08

Family

ID=69845552

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021009796A MX2021009796A (es) 2019-02-13 2020-02-13 Inhibidores selectivos de la proteina arginina metiltransferasa 5 (prmt5).

Country Status (11)

Country Link
US (1) US20220160713A1 (es)
EP (1) EP3924360A1 (es)
JP (1) JP2022521491A (es)
KR (1) KR20210129051A (es)
CN (1) CN113811539A (es)
AU (1) AU2020223058A1 (es)
BR (1) BR112021015796A2 (es)
CA (1) CA3129612A1 (es)
IL (1) IL285536A (es)
MX (1) MX2021009796A (es)
WO (1) WO2020168125A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11077101B1 (en) 2018-07-18 2021-08-03 Tango Therapeutics, Inc. Compounds and methods of use
MX2023001379A (es) 2020-07-31 2023-06-15 Tango Therapeutics Inc Derivados de piperidin-1-il-n-piridina-3-il-2-oxoacet amida utiles para el tratamiento de canceres deficientes en mtap y/o que acumulan mt a.
WO2022125735A1 (en) 2020-12-10 2022-06-16 Prelude Therapeutics Incorporated Processes for making prmt5 inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657744A (en) 1970-05-08 1972-04-25 Univ Minnesota Method for fixing prosthetic implants in a living body
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5040548A (en) 1989-06-01 1991-08-20 Yock Paul G Angioplasty mehtod
US5061273A (en) 1989-06-01 1991-10-29 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US5350395A (en) 1986-04-15 1994-09-27 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US4748982A (en) 1987-01-06 1988-06-07 Advanced Cardiovascular Systems, Inc. Reinforced balloon dilatation catheter with slitted exchange sleeve and method
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
CA1322628C (en) 1988-10-04 1993-10-05 Richard A. Schatz Expandable intraluminal graft
US6344053B1 (en) 1993-12-22 2002-02-05 Medtronic Ave, Inc. Endovascular support device and method
US5674278A (en) 1989-08-24 1997-10-07 Arterial Vascular Engineering, Inc. Endovascular support device
US5292331A (en) 1989-08-24 1994-03-08 Applied Vascular Engineering, Inc. Endovascular support device
EP3160477A4 (en) * 2014-06-25 2018-07-04 Epizyme, Inc. Prmt5 inhibitors and uses thereof
EA031895B1 (ru) * 2015-02-24 2019-03-29 Пфайзер Инк. Замещенные нуклеозидные производные, полезные в качестве агентов против рака
AR104326A1 (es) * 2015-05-04 2017-07-12 Lilly Co Eli Compuestos nucleósidos 5-sustituidos
TW202321249A (zh) * 2015-08-26 2023-06-01 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６－６雙環芳香環取代之核苷類似物
CA3072439A1 (en) * 2017-08-09 2019-02-14 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2020033285A1 (en) * 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors

Also Published As

Publication number Publication date
IL285536A (en) 2021-09-30
CN113811539A (zh) 2021-12-17
EP3924360A1 (en) 2021-12-22
BR112021015796A2 (pt) 2021-10-13
AU2020223058A1 (en) 2021-09-09
WO2020168125A1 (en) 2020-08-20
JP2022521491A (ja) 2022-04-08
CA3129612A1 (en) 2020-08-20
KR20210129051A (ko) 2021-10-27
US20220160713A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
MX2020001598A (es) Inhibidores selectivos de proteína arginina metiltransferasa 5 (prmt5).
PH12019502052A1 (en) Hepatitis b virus surface antigen inhibitor
MX2021005463A (es) Derivados de espiro-sulfonamida como inhibidores de la proteina de leucemia de celula mieloide 1 (mcl-1).
MX2021009796A (es) Inhibidores selectivos de la proteina arginina metiltransferasa 5 (prmt5).
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
PH12014501134A1 (en) 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
EA202091016A1 (ru) Пиримидиновое соединение в качестве ингибитора jak киназы
MX2021006265A (es) Derivados de panteteina y usos de los mismos.
PH12020552017A1 (en) 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof
EA200870302A1 (ru) 1,3-диоксанкарбоновые кислоты
MX2021000093A (es) Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos.
TW200745097A (en) 4-Phenyl-thiazole-5-carboxylic acids and 4-phenyl-thiazole-5-carboxylic acid amides as PLK1 inhibitors
MX2023003264A (es) Inhibidores de cdk y su uso como productos fármaceuticos.
MD20160105A2 (ro) 2-Amino-6-metil-4,4a,5,6-tetrahidropirano[3,4-d][1,3]tiazin-8a(8H)-il-1,3-tiazol-4-il amide
MX2021009659A (es) Hidroxipiridoxazepinas como activadores de nrf2.
MX2022001789A (es) Derivados de 2-hidroxicicloalcan-1-carbamoilo.
MX2020009555A (es) Inhibidores selectivos de proteina arginina-metiltransferasa 5 (prmt5).
PH12020551494A1 (en) Substituted imidazolidin-2-one derivatives as prmt5 inhibitors
MX2019006612A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta).
BR112021011325A2 (pt) Derivados de rapamicina
MX2020002630A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta.
WO2018085833A3 (en) Selective inhibitors of protein arginine methyl transferase 5 (prmt5)
MY195576A (en) Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof
MX2018010177A (es) Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxa mida.
MX2022003340A (es) Inhibidores selectivos de la proteina arginina metiltransferasa 5 (prmt5).